Avidity Biosciences Stock Probability of Future Stock Price Finishing Under 17.85
| RNA Stock | USD 31.82 0.77 2.48% |
Avidity |
Avidity Biosciences Target Price Odds to finish below 17.85
The tendency of Avidity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 17.85 or more in 90 days |
| 31.82 | 90 days | 17.85 | near 1 |
Based on a normal probability distribution, the odds of Avidity Biosciences to drop to $ 17.85 or more in 90 days from now is near 1 (This Avidity Biosciences probability density function shows the probability of Avidity Stock to fall within a particular range of prices over 90 days) . Probability of Avidity Biosciences price to stay between $ 17.85 and its current price of $31.82 at the end of the 90-day period is near 1 .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.93 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Avidity Biosciences will likely underperform. Additionally Avidity Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Avidity Biosciences Price Density |
| Price |
Predictive Modules for Avidity Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Avidity Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Avidity Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Avidity Biosciences is not an exception. The market had few large corrections towards the Avidity Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Avidity Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Avidity Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.51 | |
β | Beta against Dow Jones | 1.93 | |
σ | Overall volatility | 4.84 | |
Ir | Information ratio | -0.11 |
Avidity Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Avidity Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Avidity Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Avidity Biosciences generated a negative expected return over the last 90 days | |
| Avidity Biosciences has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 9.56 M. Reported Net Loss for the year was (212.22 M) with loss before taxes, overhead, and interest of (141.18 M). | |
| Avidity Biosciences has about 398.22 M in cash with (119.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing |
Avidity Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Avidity Stock often depends not only on the future outlook of the current and potential Avidity Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Avidity Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 73 M | |
| Cash And Short Term Investments | 595.4 M |
Avidity Biosciences Technical Analysis
Avidity Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Avidity Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Avidity Biosciences. In general, you should focus on analyzing Avidity Stock price patterns and their correlations with different microeconomic environments and drivers.
Avidity Biosciences Predictive Forecast Models
Avidity Biosciences' time-series forecasting models is one of many Avidity Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Avidity Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Avidity Biosciences
Checking the ongoing alerts about Avidity Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Avidity Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Avidity Biosciences generated a negative expected return over the last 90 days | |
| Avidity Biosciences has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 9.56 M. Reported Net Loss for the year was (212.22 M) with loss before taxes, overhead, and interest of (141.18 M). | |
| Avidity Biosciences has about 398.22 M in cash with (119.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing |
Check out Avidity Biosciences Backtesting, Avidity Biosciences Valuation, Avidity Biosciences Correlation, Avidity Biosciences Hype Analysis, Avidity Biosciences Volatility, Avidity Biosciences History as well as Avidity Biosciences Performance. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share 0.103 | Quarterly Revenue Growth (0.17) | Return On Assets (0.18) | Return On Equity (0.28) |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.